StreetInsider.com News Articles

Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 05 Oct 2026 16:01:00 -0400

PHILADELPHIA, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced the grant of inducement equity awards to four newly hired non-executive employees as a material inducement to commencing their employment with the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement awards are as follows: (i) non-qualified stock options to purchase an aggregate of 200,000 shares of the Company’s common stock with an exercise price of

Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 05 Oct 2026 16:01:00 -0400

The inducement awards are as follows: (i) non-qualified stock options to purchase an aggregate of 200,000 shares of the Company’s common stock with an exercise price of

Form 8-K Cabaletta Bio, Inc. For: Sep 14

Mon, 14 Sep 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260914/27055710.html

TD Cowen Assumes Cabaletta Bio (CABA) at Buy

Sat, 22 Aug 2026 07:55:00 -0400

TD Cowen analyst Phil Nadeau assumes coverage on Cabaletta Bio (NASDAQ: CABA) with a Buy rating.

For an analyst ratings summary and ratings history on Cabaletta Bio click here. For more ratings news on Cabaletta Bio click here.

Shares of Cabaletta Bio closed at $3.13 yesterday.

Form SCHEDULE 13G/A Cabaletta Bio, Inc. Filed by: Cormorant Asset Management, LP

Fri, 14 Aug 2026 14:01:00 -0400

si-local-file:///var/storage/secattach/20260814/26928704.html

Form SCHEDULE 13G/A Cabaletta Bio, Inc. Filed by: Cormorant Asset Management, LP

Fri, 14 Aug 2026 14:01:00 -0400

si-local-file:///var/storage/secattach/20260814/26928704.html

Form SCHEDULE 13G/A Cabaletta Bio, Inc. Filed by: T. Rowe Price Investment Management, Inc.

Fri, 14 Aug 2026 10:40:00 -0400

si-local-file:///var/storage/secattach/20260814/26926656.html

Form SCHEDULE 13G/A Cabaletta Bio, Inc. Filed by: T. Rowe Price Investment Management, Inc.

Fri, 14 Aug 2026 10:40:00 -0400

si-local-file:///var/storage/secattach/20260814/26926656.html

Cabaletta Bio (CABA) PT Lowered to $3 at Wells Fargo

Fri, 14 Aug 2026 08:51:55 -0400

Wells Fargo analyst Derek Archila lowered the price target on Cabaletta Bio (NASDAQ: CABA) to $3.00 (from $4.00) while maintaining a Equal Weight rating.

Form SCHEDULE 13G/A Cabaletta Bio, Inc. Filed by: Bain Capital Life Sciences Opportunities III, LP

Fri, 14 Aug 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260814/26924420.html

Form SCHEDULE 13G/A Cabaletta Bio, Inc. Filed by: Bain Capital Life Sciences Opportunities III, LP

Fri, 14 Aug 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260814/26924420.html

TD Cowen: 'CABA appears well-positioned to scale commercially with minimal capital investment'

Thu, 13 Aug 2026 10:32:03 -0400

TD Cowen analyst Phil Nadeau reiterated a Buy rating on Cabaletta Bio (NASDAQ: CABA).

The analyst comments "Cabaletta continues to execute across its portfolio of RESET trials. The RESET-Myositis pivotal trial is on track for data Mid:27 with a BLA including juveniles in H2:27. Notably, data presented at EULAR (detailed here) supports pivotal development of rese-cel in SSc-associated ILD and juvenile myositis. Recall, rese-cel treatment in SSc-ILD patients led to a median FVC improvement of ~8% at 26 weeks, in contrast to SoC agents that slow decline but are not associated with improvement. This appears to be a meaningful potential advance,

Form 10-Q Cabaletta Bio, Inc. For: Jun 30

Thu, 13 Aug 2026 07:35:00 -0400

si-local-file:///var/storage/secattach/20260813/26916538.html

Form 10-Q Cabaletta Bio, Inc. For: Jun 30

Thu, 13 Aug 2026 07:35:00 -0400

si-local-file:///var/storage/secattach/20260813/26916538.html

Form 8-K Cabaletta Bio, Inc. For: Aug 13

Thu, 13 Aug 2026 07:32:00 -0400

si-local-file:///var/storage/secattach/20260813/26916529.html

Form 8-K Cabaletta Bio, Inc. For: Aug 13

Thu, 13 Aug 2026 07:32:00 -0400

si-local-file:///var/storage/secattach/20260813/26916529.html

Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 13 Aug 2026 07:30:00 -0400

Registrational RESET-Myositis^® clinical data on track to be reported in mid-2027 to support 2H27 BLA submission for rese-cel

Juvenile myositis Phase 1/2 data expected to be submitted with BLA to support potential FDA Priority Review Voucher

Registrational RESET-SSc^® enrollment in approximately 25 patients with SSc-associated interstitial lung disease anticipated to initiate in 4Q26

PC-free approach being incorporated in RESET-MG^® based on emerging insights from PC-free RESET-SLE^® and RESET-PV^® cohorts and previously reported Phase 1/2 clinical data

Pursuing expansion of outpatient dosing option for rese-cel within the RESET™ clinical development program

Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 13 Aug 2026 07:30:00 -0400

Registrational RESET-Myositis^® clinical data on track to be reported in mid-2027 to support 2H27 BLA submission for rese-cel

Juvenile myositis Phase 1/2 data expected to be submitted with BLA to support potential FDA Priority Review Voucher

Registrational RESET-SSc^® enrollment in approximately 25 patients with SSc-associated interstitial lung disease anticipated to initiate in 4Q26

PC-free approach being incorporated in RESET-MG^® based on emerging insights from PC-free RESET-SLE^® and RESET-PV^® cohorts and previously reported Phase 1/2 clinical data

Pursuing expansion of outpatient dosing option for rese-cel within the RESET™ clinical development program

Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 13 Aug 2026 07:30:00 -0400

Registrational RESET-Myositis^® clinical data on track to be reported in mid-2027 to support 2H27 BLA submission for rese-cel

Juvenile myositis Phase 1/2 data expected to be submitted with BLA to support potential FDA Priority Review Voucher

Registrational RESET-SSc^® enrollment in approximately 25 patients with SSc-associated interstitial lung disease anticipated to initiate in 4Q26

PC-free approach being incorporated in RESET-MG^® based on emerging insights from PC-free RESET-SLE^® and RESET-PV^® cohorts and previously reported Phase 1/2 clinical data

Pursuing expansion of outpatient dosing option for rese-cel within the RESET™ clinical development program

Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 13 Aug 2026 07:30:00 -0400

Registrational RESET-Myositis^® clinical data on track to be reported in mid-2027 to support 2H27 BLA submission for rese-cel

Juvenile myositis Phase 1/2 data expected to be submitted with BLA to support potential FDA Priority Review Voucher

Registrational RESET-SSc^® enrollment in approximately 25 patients with SSc-associated interstitial lung disease anticipated to initiate in 4Q26

PC-free approach being incorporated in RESET-MG^® based on emerging insights from PC-free RESET-SLE^® and RESET-PV^® cohorts and previously reported Phase 1/2 clinical data

Pursuing expansion of outpatient dosing option for rese-cel within the RESET™ clinical development program

Form SCHEDULE 13G/A Cabaletta Bio, Inc. Filed by: Adage Capital Management, L.P.

Wed, 12 Aug 2026 12:06:00 -0400
si-local-file:///var/storage/secattach/20260812/26911248.html

Form SCHEDULE 13G/A Cabaletta Bio, Inc. Filed by: Adage Capital Management, L.P.

Wed, 12 Aug 2026 12:06:00 -0400
si-local-file:///var/storage/secattach/20260812/26911248.html

Form SCHEDULE 13G Cabaletta Bio, Inc. Filed by: NORGES BANK

Wed, 12 Aug 2026 06:36:00 -0400
si-local-file:///var/storage/secattach/20260812/26908525.html

Form SCHEDULE 13G Cabaletta Bio, Inc. Filed by: NORGES BANK

Wed, 12 Aug 2026 06:36:00 -0400
si-local-file:///var/storage/secattach/20260812/26908525.html

Form SCHEDULE 13G Cabaletta Bio, Inc. Filed by: VANGUARD CAPITAL MANAGEMENT LLC

Fri, 31 Jul 2026 09:55:00 -0400
si-local-file:///var/storage/secattach/20260731/26847978.html